文献速递胸部肿瘤泌尿男性生殖肿瘤骨软组织肉瘤与黑色素瘤

抗PD-1药物临床实践采纳速度及患者年龄与关键试验比较

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
PubMed 文献 · JAMA Oncol · 2018-08-09

该回顾性队列研究纳入Flatiron Health网络中3089例符合抗PD-1药物治疗的黑色素瘤、非小细胞肺癌和肾细胞癌患者,评估药物采纳速度并比较实践与关键试验患者年龄。结果显示68.7%的患者接受了治疗,FDA批准后4个月内各队列超过60%的合格患者接受治疗;临床实践中65岁以上患者比例显著高于关键试验(范围60.6%-63.9% vs 31.7%-41.0%,所有P<.001)。

要点

  • 抗PD-1药物在FDA批准后4个月内快速覆盖超过60%的合格患者。
  • 临床实践中65岁以上患者比例显著高于关键临床试验。
  • 未来需确保快速采纳基于代表性试验证据。

核心结论

  • 抗PD-1药物迅速到达临床实践中的患者,但实践治疗患者与关键临床试验患者年龄存在显著差异。

研究设计与样本

  • 回顾性队列研究,2011年1月1日至2016年8月31日,纳入Flatiron Health网络3089例符合抗PD-1药物治疗的黑色素瘤、非小细胞肺癌和肾细胞癌患者。

主要发现

  • 3089例合格患者中2123例(68.7%)接受了抗PD-1药物治疗,包括黑色素瘤439例(79.1%)、NSCLC 1417例(65.6%)和RCC 267例(71.2%)。
  • FDA批准后4个月内,每个队列中超过60%的合格患者接受了抗PD-1药物治疗。
  • 临床实践中65岁以上患者比例范围为60.6%(327/1365)至63.9%(46/72),关键临床试验为31.7%(38/120)至41.0%(223/544),所有P<.001。

临床怎么用

  • 抗PD-1药物在临床实践中快速普及,但需关注实践患者与试验人群的年龄差异对疗效和安全性的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The US Food and Drug Administration (FDA) is increasing its pace of approvals for novel cancer therapeutics, including for immune checkpoint inhibitors of programmed cell death 1 protein (anti-PD-1 agents). However, little is known about how quickly anti-PD-1 agents agents reach eligible patients in practice or whether such patients differ from those studied in clinical trials that lead to FDA approval (pivotal clinical trials). OBJECTIVES: To assess the speed with which anti-PD-1 agents agents reached eligible patients in practice and to compare the ages of patients treated in clinical practice with the ages of those treated in pivotal clinical trials. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study, performed from January 1, 2011, through August 31, 2016, included patients from the Flatiron Health Network who were eligible for anti-PD-1 agents treatment of selected cancer types, which included melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). MAIN OUTCOMES AND MEASURES: Cumulative proportions of eligible patients receiving anti-PD-1 agents treatment and their age distributions. RESULTS: The study identified 3089 patients who were eligible for anti-PD-1 agents treatment (median age, 66 [interquartile range, 56-75] years for patients with melanoma, 66 [interquartile range, 58-72] years for patients with RCC, and 67 [interquartile range, 59-74] years for patients with NSCLC; 1742 male [56.4%] and 1347 [43.6%] female; 2066 [66.9%] white). Of these patients, 2123 (68.7%) received anti-PD-1 agents treatment, including 439 eligible patients with melanoma (79.1%), 1417 eligible patients with NSCLC (65.6%), and 267 eligible patients with RCC (71.2%). Within 4 months after FDA approval, greater than 60% of eligible patients in each cohort had received anti-PD-1 agents treatment. Overall, similar proportions of older and younger patients received anti-PD-1 agents treatment during the first 9 months after FDA approval. However, there were significant differences in age between clinical trial participants and patients receiving anti-PD-1 agents treatment in clinical practice, with more patients being older than 65 years in clinical practice (range, 327 of 1365 [60.6%] to 46 of 72 [63.9%]) than in pivotal clinical trials (range, 38 of 120 [31.7%] to 223 of 544 [41.0%]; all P < .001). CONCLUSIONS AND RELEVANCE: Anti-PD-1 agents rapidly reached patients in clinical practice, and patients treated in clinical practice differed significantly from patients treated in pivotal clinical trials. Future actions are needed to ensure that rapid adoption occurs on the basis of representative trial evidence.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. O'Connor JM, Fessele KL, Steiner J, et al. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncol. 2018. PMID: 29800974. doi:10.1001/jamaoncol.2018.0798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。